Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis IOBL07
- Development stage
- Unknown
- Lead developer
- International Flavors & Fragrances
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis IOBL07 is a specific probiotic strain developed by I-O Corporation, primarily used to support gastrointestinal health. As a live biotherapeutic, it functions by colonizing the human gut, where it modulates the composition of the microbiota and produces organic acids, such as lactic and acetic acids. These metabolites lower the intestinal pH, inhibiting the growth of pathogenic bacteria and promoting a favorable environment for beneficial microbes. Clinical studies have demonstrated that IOBL07 can significantly improve bowel movement frequency and stool consistency in individuals prone to constipation. Additionally, it is thought to enhance the intestinal barrier function and interact with the gut-associated lymphoid tissue (GALT) to support immune homeostasis.
- Other names
- B. lactis IOBL07Bifidobacterium lactis IOBL07
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis IOBL07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis IOBL07.